SpringWorks Therapeutics, Inc. (SWTX)
Largest Insider Buys in Sector
SWTX Stock Price History Chart
SWTX Stock Performance
About SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a …
Insider Activity of SpringWorks Therapeutics, Inc.
Over the last 12 months, insiders at SpringWorks Therapeutics, Inc. have bought $0 and sold $10.9M worth of SpringWorks Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at SpringWorks Therapeutics, Inc. have bought $0 and sold $98.83M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 50,000 shares for transaction amount of $900,000 was made by PFIZER INC (10 percent owner) on 2019‑09‑17.
List of Insider Buy and Sell Transactions, SpringWorks Therapeutics, Inc.
| 2024-12-03 | Sale | Chief Operating Officer | 20,000 0.0266% | $41.97 | $839,336 | -6.58% | ||
| 2024-12-02 | Sale | Chief Executive Officer | 49,000 0.0648% | $41.37 | $2.03M | -2.90% | ||
| 2024-09-03 | Sale | Chief Executive Officer | 49,000 0.0644% | $40.57 | $1.99M | -14.90% | ||
| 2024-09-03 | Sale | Chief Operating Officer | 20,000 0.0263% | $40.65 | $812,954 | -14.90% | ||
| 2024-06-03 | Sale | Chief Executive Officer | 49,000 0.0634% | $39.90 | $1.96M | -6.42% | ||
| 2024-06-03 | Sale | Chief Operating Officer | 20,000 0.026% | $40.07 | $801,372 | -6.42% | ||
| 2024-06-03 | Sale | director | 4,648 0.006% | $40.03 | $186,048 | -6.42% | ||
| 2024-02-16 | Sale | Chief People Officer | 15,000 0.0244% | $50.10 | $751,550 | -25.16% | ||
| 2024-02-05 | Sale | Chief Commercial Officer | 4,834 0.0077% | $49.32 | $238,435 | -17.59% | ||
| 2024-02-02 | Sale | Chief Commercial Officer | 3,222 0.0046% | $44.37 | $142,976 | -13.97% | ||
| 2024-02-02 | Sale | Chief People Officer | 26,181 0.0376% | $44.32 | $1.16M | -13.97% | ||
| 2023-07-19 | Sale | director | 2,418 0.0023% | $29.31 | $70,876 | +28.19% | ||
| 2023-06-20 | Sale | director | 2,400 0.0021% | $26.92 | $64,603 | +25.62% | ||
| 2023-03-16 | Sale | director | 1.75M 1.6164% | $28.50 | $49.88M | -7.34% | ||
| 2023-03-15 | Sale | director | 1,106 0.0011% | $31.50 | $34,841 | -12.45% | ||
| 2023-01-26 | Sale | Chief People Officer | 858 0.0009% | $31.00 | $26,598 | -8.01% | ||
| 2022-09-12 | Sale | 10 percent owner | 153,897 0.1594% | $31.96 | $4.92M | -15.10% | ||
| 2022-08-09 | Sale | 10 percent owner | 69,568 0.0845% | $37.47 | $2.61M | -24.92% | ||
| 2022-08-08 | Sale | 10 percent owner | 205,000 0.2547% | $38.33 | $7.86M | -31.82% | ||
| 2022-08-08 | Sale | 69,568 0.0845% | $37.47 | $2.61M | -31.82% |
Insider Historical Profitability
| ORBIMED ADVISORS LLC | 10 percent owner | 5599842 7.528% | $35.59 | 1 | 13 | +41.34% |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 4831307 6.4949% | $35.59 | 1 | 2 | +41.34% |
| PFIZER INC | 10 percent owner | 4593847 6.1757% | $35.59 | 1 | 0 | +41.34% |
| Lewis-Hall Freda C | 4593847 6.1757% | $35.59 | 1 | 0 | +41.34% | |
| SQUINTO STEPHEN P | 125728 0.169% | $35.59 | 1 | 4 | +41.34% |